SCYNEXIS, Inc. (NASDAQ:SCYX – Get Free Report) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.49 and traded as low as $1.11. SCYNEXIS shares last traded at $1.12, with a volume of 112,390 shares changing hands.
Analyst Upgrades and Downgrades
Separately, StockNews.com raised shares of SCYNEXIS from a “sell” rating to a “hold” rating in a report on Friday, November 8th.
View Our Latest Report on SCYNEXIS
SCYNEXIS Stock Performance
SCYNEXIS (NASDAQ:SCYX – Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.14. The firm had revenue of $0.66 million for the quarter. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%.
Institutional Trading of SCYNEXIS
A hedge fund recently bought a new stake in SCYNEXIS stock. XTX Topco Ltd acquired a new position in shares of SCYNEXIS, Inc. (NASDAQ:SCYX – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 17,111 shares of the company’s stock, valued at approximately $25,000. Institutional investors and hedge funds own 54.37% of the company’s stock.
About SCYNEXIS
SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
See Also
- Five stocks we like better than SCYNEXIS
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- Golden Cross Stocks: Pattern, Examples and Charts
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- What is an Earnings Surprise?
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.